Tyrosine kinase inhibitor-resistant glioblastomas can be resensitized to EGFR tyrosine kinase inhibitors by pharmacologic inhibition of MEK or a BH3 mimetic drug to replace Bim function [313]. This evidence concerns the gene BCL2L11 and glioblastoma.